Flexi-Pricing Scheme Unveiled For Novartis AG (ADR) (NVS) Kisqali In The Face Of Stiff Competition
After recently getting the approval of the U.S.
Posts Tagged ‘Is NVS A Good Stock To Buy Right Now?’
Positive Results For AbbVie Inc (ABBV) Humira Biosimilar Reported By Novartis AG (ADR) (NVS)
A Phase III study has shown that GP2017, which is manufactured by Sandoz, a unit of Novartis AG (ADR) (NYSE:NVS), has shown positive results as a Humira biosimilar.
Novartis AG (ADR) (NVS) Fined And Some Products To Be Temporarily Suspended In South Korea
Novartis AG (ADR) (NYSE:NVS) has been fined approximately $174,000 in South Korea after the company was found guilty of bribing physicians in order to induce them to recommend...
Novartis AG (ADR) (NVS) Greater Use Of Technology In Transforming Medical Education
Novartis AG (ADR) (NYSE:NVS) is quickly entering into an engagement with the use of digital technology.
Novartis AG (ADR) (NVS) Agrees To $50 Million Deal With Conatus Pharmaceuticals Inc (CNAT)
Novartis AG (ADR) (NYSE:NVS) and Conatus Pharmaceuticals Inc (NASDAQ:CNAT) will jointly develop Conatus drug emricasan.
Novartis AG (ADR) (NVS) Acquires Selexys Pharmaceuticals Corp.
Novartis AG (ADR) (NYSE:NVS) has recently acquired Selexys Pharmaceuticals Corp.
Novartis AG (ADR) (NVS) And Pfizer Inc. (PFE) Are In A Race To Gain Favor In Breast Cancer
Novartis AG (ADR) (NYSE:NVS) CDK4/6 breast cancer drug remains on track with Pfizer Inc. (NYSE:PFE)'s Ibrance.
Novartis AG (NVS) Relocates NITD To California
James Bradner, Novartis AG (NYSE:NVS) Novartis Institutes for BioMedical Research President, has recently confirmed that the company will move the Novartis Institute for Tropical...
Does Novartis AG (NVS) Have The Solution For Malaria?
Results for a potentially game-changing proof of concept study were just published concerning malaria by Novartis AG (NYSE:NVS) in the New England Journal of Medicine.
Here’s What’s Important With The Novartis AG (ADR) (NVS) MS Data
Novartis AG (ADR) (NYSE:NVS) just put out data from its multiple sclerosis (MS) trial, and it looks as if the company is winning the race to bring a drug to market that offers...
Novartis AG (NVS) Announces Positive Phase III Results For MS Drug
Novartis AG (NYSE:NVS) has announced that the Phase III EXPAND study, which is evaluating the efficacy and safety of oral, once daily, BAF312 in secondary progressive multiple...
Colombia Makes Good On Its Threat Against Novartis AG (NVS)
After negotiations with Novartis AG (NYSE:NVS) to lower the price of key leukemia drug Gleevec broke off, the Colombian government is set to take matters into its own hands.
